Preclinical services from a top preclinical CRO in Kiev, UA.
Our company is an independent Contract Research Organization operating out of the U.S. that conducts preclinical drug toxicology in top-notch, Good Laboratory Practices certified research facilities in Kiev, UA. Our testing sites are supported by the Ukrainian National Academy of Medical Sciences and Ministry of Health and offer support for for-profit development of new drug discoveries as part of their core mission. Our business was created to provide the top-notch, lower cost services of these laboratories to start-up bio-technology companies in the United States and Europe, thereby offering a smart option for promoting development programs rapidly and at much lower cost than other commercial CROs. We offer a wide range of pre-clinical research including drug safety, chronic and acute toxicity, pharma screening, bioavailability, bioequivalence, and extensive in vivo and in vitro screening for anti-cancer activity.
Our pre-clinical Contract Research Organization is able to price preclinical toxicology far below other CROs because we have a very low overhead in the USA and perform all trials in Kiev where labor and laboratory costs are much lower. Our staff in the U.S. is comprised of only of the company principals who deal directly with clients; we don’t have any promotion expenses aside from our website, and no head offices, administrative staff or other overhead to increase costs. We have much lower study conduct costs in Ukraine due to much lower workers rates and are able to offer our best pricing for longer and more intricate preclinical tests where labor is the greatest part of the overall cost. Since we use the same stable international providers for animal models, reagents and laboratory supplies as other Contract Research Organizations, we don’t have any cost advantage on these materials and so less overall cost savings for very short-term pre-clinical trials. But, regardless of your study protocol and duration, our goal is to provide our clients the greatest possible value for their investment.